A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

NCT04007107 · Completed

Last updated 2026-05-28

This clinical trial compares the pain at the injection site when healthy volunteers with type 2 diabetes, overweight, or obesity receive two different forms of semaglutide using two different injection pens.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 103 people

Who can join Ages 18–75 · all sexes Healthy volunteers accepted.

Timeline Started 2019-06 · est. completion 2019-09

Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT04007107 ↗

Description as written by the study sponsor.

This study in healthy men and women compares the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (sc, under the skin). Participants will receive 2 single doses of semaglutide 0.25 mg on 1 day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Treatments tested

Semaglutide (administered by DV3396 pen) Drug

Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day
Semaglutide (administered by PDS290 pen) Drug

Subjects will receive 1 single dose of semaglutide 0.25 mg on 1 day

Main thing measured	Intensity of Injection Site Pain
Sponsor	Novo Nordisk A/S
Conditions studied	Healthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04007107 ↗